Hyper IgE in stimulatory graft- versus-host disease: role of interleukin-4

Interleukin 7 worsens graft-versus-host disease.

Impaired immune reconstitution has moved to the forefront of clinical problems limiting progress in allogeneic bone marrow transplantation (BMT). The identification of therapies that can enhance immune reconstitution by increasing thymopoiesis is critical to solving this problem. Interleukin 7 (IL-7) is the most potent thymopoietic cytokine identified thus far. To study the effects of IL-7 on i...

Interleukin-12 inhibits murine graft-versus-host disease.

Interleukin-12 (IL-12) is a potent immunostimulatory cytokine and an inducer of type-1 T-helper cell activity and of cytotoxic T lymphocyte and natural killer cell function. We report here the paradoxical observation that a single injection of 4,900 IU of recombinant murine IL-12 inhibits acute graft-versus-host disease (GVHD) in a fully major histocompatibility complex (MHC) plus multiple mino...

Graft Versus Host Disease

Commonly referred to as GVHD, graft-versus-host disease is a man-made condition that arises when patients are transplanted with donor tissue that is not identical to their own. Transplants from other individuals are called allogeneic (‘allo’ meaning ‘other’ and ‘geneic’ referring to ‘genes’). GVHD occurs after hematopoietic stem cell or bone marrow transplantation but is most commonly experienc...

Graft versus Host Disease

Definition Graft-versus-host disease (GVHD) is the most common complication of allogeneic hematopoietic stem cell transplantation (HSCT). In HSCT, the patient’s bone marrow is destroyed with chemotherapy and/or radiation and replaced by donor hematopoietic stem cells. In allogeneic HSCT the donor is usually a close family member or occasionally someone outside the family who has been found to b...

Graft-versus-host disease or graft-versus-host-like syndrome.